Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 598	$ 3,193
Property, plant and improvements
Property and equipment, net	152,721	166,509
Other assets
Operating lease right-of-use assets	236,307
Other receivable	422,034	418,905
Note receivable – related party	44,859	44,859
Advances to CEN Biotech Ukraine LLC – related party	1,035,328	875,328
Intangible asset, net	5,487,162	5,805,771
Total assets	7,379,009	7,314,565
Current liabilities
Accounts payable	208,789	206,521
Loans payable	10,115,713	10,107,205
Loans payable – related parties	1,361,881	1,360,806
Convertible notes payable	4,823,238	3,597,760
Convertible notes payable – related parties	2,538,681	926,368
Accrued interest	8,903,940	6,860,494
Accrued interest – related parties	1,201,729	946,227
Operating lease liabilities	42,650
Accrued expenses	526,233	402,377
Total current liabilities	29,722,854	24,407,758
Operating lease liabilities, less current portion	191,925
Patent acquisition liability	1,010,000	1,010,000
Convertible notes, less current portion	1,028,487	1,545,887
Convertible notes – related parties, less current portion	20,000	1,612,313
Total liabilities	31,973,266	28,575,958
Shareholders’ deficit
Common stock; unlimited authorized shares; 26,858,363 and 25,473,363 issued and outstanding as of September 30, 2019 and December 31, 2018, respectively. No par value.
Additional paid-in capital	15,486,710	14,393,660
Accumulated deficit	(40,080,967)	(35,655,053)
Total shareholders’ deficit	(24,594,257)	(21,261,393)
Total liabilities and shareholders’ deficit	$ 7,379,009	$ 7,314,565